This study investigated the differences in the effect of an angiotensin converting enzyme inhibitor (ACEI) compared with an angiotensin receptor blocker (ARB) on blood pressure (BP) and pulse pressure (PP) measured in the clinic (CBP and CPP, respectively), at home (HBP, HPP) and with ambulatory monitoring (ABP, APP). Twenty-seven hypertensive patients were randomised to receive lisinopril (20 mg) or losartan (50 mg) for 5 weeks, and were subsequently crossed-over to the alternative treatment for a second 5-week period. Measurements of CBP, 24-h ABP and 5-days HBP were performed before randomisation and at the end of each treatment period. All measurement methods showed that lisinopril was more effective than losartan in reducing BP. However, the difference between the two drugs was demonstrated with greater precision using HBP (Po0.001) than 24-h ABP (Po0.01), whereas the poorest precision for demonstrating this difference was provided by CBP (Po0.05). Lisinopril was also found more effective than losartan in reducing HPP (P ¼ 0.01) and 24-h APP (P ¼ 0.03) whereas no such a difference was detected using measurements of CPP. It was concluded that the antihypertensive drugs may differ in their effects not only on BP, but also on PP. HBP monitoring appears to be as reliable as 24-h ABP monitoring in detecting differences in the effect of drugs on both BP and PP. Clinic measurements seem to be the least reliable method, particularly in the detection of differences in PP.
Introduction
Measurement of blood pressure in the clinic (CBP) is regarded as the cornerstone of the diagnosis and management of hypertension because of its proven relationship with cardiovascular risk. However, CBP has several major drawbacks, such as observer bias, the white coat effect and the placebo effect, and therefore has limited reproducibility. 1, 2 In view of these limitations, during the last 15 years alternative out-of-office measurement methods have been introduced. Ambulatory blood pressure (ABP) monitoring has found an important role in clinical pharmacology because it is more reproducible than CBP and provides information on the time-effect profile of antihypertensive drug action. 3, 4 Likewise, home monitoring of blood pressure (HBP) is being increasingly used in clinical practice and research, since accumulating data suggest that it is highly reproducible 5 and is free of the white coat effect 6 and the placebo effect. 7 Recently, pulse pressure (PP) has been recognised as an independent predictor of cardiovascular risk. 8 There is evidence that in some populations, the predictive value of PP may be superior to that of systolic, diastolic or mean blood pressure (BP). 9, 10 In elderly subjects, in particular, a 10 mmHg wider PP has been found to be associated with a 13% increase in the risk for coronary events and 20% for cardiovascular mortality. 11 In middle-aged hypertensives, ambulatory PP (APP) has also been shown to provide independent prognostic information for cardiovascular morbidity. 12 Therefore, recent studies have focused on the effect of drugs not only on BP but also on PP. [13] [14] [15] Although in most of the studies PP has been obtained using measurements of CBP, there is some evidence showing that APP is lower than clinic PP (CPP) 12, 14 and may be superior to the latter in predicting cardiovascular events. 12 Values of PP obtained using home measurements (HPP) have never been studied.
The objective of this study was to investigate differences in the effect of two drugs, an angiotensin converting enzyme inhibitor (ACEI) and an angiotensin receptor blocker (ARB), on BP and PP measured in the clinic, at home and with ambulatory monitoring.
Subjects and methods

Study design and participants
A randomised, open-label, crossover comparative study of an ARB vs an ACEI was conducted using CBP, ABP and HBP measurements, The protocol and the process for obtaining informed consent were approved by the hospital scientific committee. Untreated subjects with diastolic CBP 90-110 mmHg on two visits were assessed with 24-h ABP monitoring. In all, 33 subjects with average awake ABP 485 mmHg were randomised to receive open treatment with the ACEI lisinopril at 20 mg o.d. or the ARB losartan at 50 mg o.d. for five weeks. Then patients were crossed-over to the alternative treatment for a second five-week period. There was no washout period between the two randomised fiveweek treatment periods. Therefore, the second treatment period also served as a washout period. Reasons for exclusion were electrocardiographic left ventricular hypertrophy, nephropathy, diabetes mellitus, known cardiovascular renal or liver disease, repeated CBP 4200/115 mmHg (systolic/diastolic) before or during the study, evidence of secondary hypertension, and unwillingness to participate in the study.
Blood pressure measurements
CBP was measured before randomisation and on the final day of each treatment period (at trough). CBP was measured by one of three physicians who fulfilled the British Hypertension Society Protocol criteria for observer agreement in BP measurement. 16 Triplicate measurements were taken at each visit after 5 min sitting at rest using a random zero sphygmomanometer (Hawksley, Sussex, England, bladder size 15 Â 35 cm, Korotkoff phase V for diastolic BP). The average of the second and third CBP of each visit was used in the analysis.
HBP was monitored for five work days and was followed by 24-h ABP monitoring before randomisation and in the end of each treatment period. HBP was measured using validated electronic devices Omron HEM-705CP (Omron Healthcare GmbH, Hamburg, Germany, bladder size 12 Â 23 cm or 14 Â 28 cm 2 where appropriate). 17 Before inclusion in the study, patients were trained in the conditions of HBP measurements and the use of the electronic devices and were instructed to make duplicate morning (06h 00-10h 00) and evening (18h 00-22h 00) measurements after 5 min sitting at rest and with 1 min between recordings. ABP was measured using non-invasive devices SpaceLabs 
Statistical analysis
Subjects with complete sets of CBP, ABP and HBP measurements throughout the study were included in the analysis. Average awake and average asleep ABP were calculated using individual patients' sleeping hours. Recordings with o30 valid measurements during the awake period were rejected. ABP readings flagged by the software of the monitors as technically erroneous were discarded, as were measurements with systolic BP o70 or 4260 mmHg or with diastolic BP o40 or 4150 mmHg. BP readings taken within the first 20 min after the monitors were attached to patients were also discarded as these were taken in the clinic environment.
The HBP readings that were 450% higher than the next highest HBP of the individual patient were considered as irrelevant and were discarded, as were readings with systolic BP o70 or 4250 mmHg or with diastolic BP o40 or 4150 mmHg. Patients who provided fewer than 16 valid HBP readings or readings taken for fewer than five days were excluded from the analysis.
The possibility of a period effect was tested by a two-sample t-test comparing the differences found between the two drugs in the first vs the second treatment period. 18 The possibility of a treatmentperiod interaction was tested by a two-sample t-test comparing the average of BP values achieved by the two drugs in the end of the first vs the second treatment period. 18 The differences in treatmentinduced changes in BP and PP were analysed. The treatment effects were compared by performing a one-sample t-test on all within-subject differences between losartan and lisinopril. 18 For each treatment effect estimation 95% confidence intervals (CIs) were calculated. Power curves for this study were drawn using the standard deviation of differences between repeated measurements taken from a previous study, which compared the reproducibility of CBP, ABP and HBP. 2 
Results
All 33 randomised patients completed the study. Data comparing the antihypertensive response to the two drugs using CBP and ABP measurements have been published. 19 In total, 28 subjects were asked to perform HBP monitoring and 27 provided complete sets of CBP, ABP and HBP data throughout the study (one subject was withdrawn because of drug-induced adverse reaction). Mean age was 46.6 7 9.1 (s.d.) years and 16 subjects were men. No evidence of a period effect or a treatment-period interaction was observed for all the variables studied, including measurements of systolic and diastolic CBP, ABP and HBP. Average CBP, awake, asleep and 24-h ABP and HBP (average of days 2-3) at baseline and after five weeks of treatment with lisinopril and losartan are shown in Table 1 . There was a greater reduction in both systolic and diastolic BP with lisinopril compared to losartan using all three measurement techniques (Table 1, Figure 1) .
When using HBPs of the initial monitoring day only, the difference in the effect of the two drugs reached statistical significance only for systolic HBP (difference 6.3 7 11.8 mmHg, 95% CI 1.6, 11.0, Po0.01 for systolic and 2.2 7 6.1 mmHg, 95% CI À0.2, 4.6, P ¼ 0.07 for diastolic). In contrast, when using average HBP of the second monitoring day, a highly significant difference in the effect of the two drugs was observed for both systolic and diastolic HBP (difference 8.9 7 9.7 mmHg, 95% CI 5.1, 12.8, Po0.001 for systolic and 6.2 7 6.5, 95% CI 3.6, 8.8, Po0.0001 for diastolic). By increasing the number of HBP monitoring days (day 2, days 2-3, 2-4 or 2-5), the 95% CIs of the difference in the effect of the two drugs became less wide (data not shown). The difference in the effect of the two drugs was demonstrated with greater precision using HBP (days 2-3, Po0.001) than CBP (Po0.05) or ABP (Po0.01) ( Table 1) .
Average CPP, awake, asleep and 24-h APP, and HPP at baseline and after five weeks of treatment with lisinopril and losartan are also shown in Table  1 . Although there was a tendency for all aspects of PP to be lower with lisinopril compared to losartan, only the decrease in awake and 24-h APP and in HPP reached statistical significance. As was the case for BP, the difference in the effect of the two drugs was demonstrated with greater precision using HPP (Po0.001) than awake (Po0.05) or 24-h ABP (Po0.01). Changes in BP and PP after each treatment period are presented in Figure 1 . Power curves drawn for this study using the three measurement methods for the assessment of differences in the effect of the two drugs on BP and PP are shown in Figure 2 .
Discussion
The present study provides a direct comparison of two antihypertensive drugs by assessing their effects on BP as well as on PP measured in the clinic, at home and with ambulatory monitoring. Overall these data suggest that there are differences in the effects of the two drugs on both BP and PP.
Effect of drugs on CBP, ABP and HBP
Although all measurement methods showed lisinopril to be more effective than losartan in reducing both systolic and diastolic BP, the difference in drug efficacy was assessed with greater precision using HBP compared to CBP or ABP (Table 1, Figure 1 ). Data in Table 1 showed that using HBP a falsepositive result (type I error) was extraordinary unlikely, being 10/30 times less probable (for systolic/diastolic BP) compared to using 24-h ABP and about 25/50 times less probable compared to using awake or asleep ABP or CBP. In fact, as suggested by 95% CIs, HBP monitoring was the only method able to ensure a clinically important difference between the drugs of at least 4/3 mmHg for systolic/diastolic BP ( Table 1 ). The advantage of HBP and ABP could be attributed at least in part to the greater number of BP measurements obtained using the last two methods. Although the precision of CBP would have been improved had more measurements been taken, the protocol of CBP measurement in this study reflects what is usually applied in clinical research and practice. It is noteworthy that, according to the present data, carefully taken CBPs using a random zero sphygmomanometer may provide values as reliable as awake or asleep ABP. Furthermore, in line with previous reports, 24-h average proved to be the most reliable aspect of ABP. 2, 20 On the other hand, HBP (average of the second and the third day) appeared to be at least as reliable as 24-h ABP.
2,21
The advantage of HBP in improving the sensitivity of clinical trials also becomes apparent in Figure 2 . Power curves drawn for this study using reproducibility values (s.d. of differences between repeated measurements) from a previous report 2 showed that although all the three BP measurement methods provide a 480% power for the detection of a 10 mmHg difference in systolic and a 5 mmHg in diastolic BP between the two drugs, there is less dispersion of the data when using HBP (Figure 2) .
The initial HBP monitoring day provided unreliable values and was unable to detect the difference Figure 1 Drug-induced changes in systolic (SBP) and diastolic blood pressure (DBP) and pulse pressure (PP) measured in the clinic, at home and with 24-h ambulatory monitoring (*Po0.05, **Po0.01, ***Po0.001 for differences between lisinopril and losartan). in drug efficacy for diastolic BP. This observation is in accord with the findings of previous studies 5, 22 that showed the initial HBP monitoring day to provide the most unstable values, thereby leading several investigators to reject those readings. It is interesting to note that, according to the present data, this drawback of the initial day is persistently present on repeated sessions of HBP monitoring (three HBP monitoring sessions five weeks apart in this study). Therefore, it seems appropriate to discard not only the initial HBP monitoring day, but also the first day of each HBP monitoring session. The variability of the differences between two mean HBP values has been shown to decrease by increasing the number of measurements contributing to each mean. 23 It has been shown that by averaging measurements of two monitoring days (after excluding the initial day), the reproducibility of HBP is improved compared to averaging HBPs of a single day, and that only minimal further improvement in the precision of the estimate of HBP can be achieved by averaging measurements of more than two days. 5 The present study showed little improvement in precision (less wide 95% CIs of the difference in the effect of the drugs) when HBPs of more than one day were averaged, compared to using HBPs of the second day only. These findings, together with previous reports showing that average HBP of two days is needed to achieve the optimum reproducibility, 2,5 support the view that the average of two monitoring days (second and third) is the minimum schedule of measurements that provides a reliable estimate of the level of HBP. 5 
Effects of drugs on CPP, APP and HPP
High PP has been established as a significant independent predictor of all-cause, cardiovascular and, particularly, coronary mortality. 8, 12, 24 In the first published study that used PP measurements in the clinic and with ambulatory monitoring for the assessment of the efficacy of antihypertensive drugs, Asmar and Lacourciere showed that two ARBs, candesartan and losartan, differ in their effects on CPP and APP. 13 However, no study has compared the effect of an ARB with that of an ACEI on PP. Furthermore, data on drug effects on HPP are lacking.
In the present study, although there was a decrease of PP with both drugs, lisinopril seemed to induce a greater reduction compared to losartan, as it was also the case for BP. However, only differences in HPP and 24-h APP reached statistical significance (Table 1) . Despite the use of a random zero sphygmomanometer, CPP proved to be the least reliable method for the detection of differences in the effect of drugs on PP as indicated by the high s.d. of the calculated difference (7.3) and the wide 95% CIs (À0.7, 5.0). Thus, measurement of CBP was unable to detect differences in the effect of the two drugs on PP. The above findings are in line with the results of our previous study 25 showing that clinic measurements provide the most variable PP values, and that a considerably larger sample size would be required to detect clinically important differences using this method compared to using APP or HPP measurements. This is in line with previous studies showing that CBP is subject to the white coat effect and the regression dilution bias, which may limit the method's reliability. 26 Power curves drawn for this study using reproducibility values from this previous report 25 showed that while 24-h APP and HPP yielded a 480% power for the detection of a 3 mmHg difference in PP between the two drugs, less than half of this power was provided by clinic measurements (approximately 40%) (Figure 2) . Interestingly, HPP was at least as effective as 24-h APP in detecting the superiority of lisinopril over losartan in the present study (Table 1, Figure 1 ). This finding confirms our previous report, 25 which showed that the reproducibility of HPP is at least as good as that of 24-h APP, and, as is the case for 24-h APP, a smaller sample size is required for comparative antihypertensive drug trials when using HPP instead of CPP. 25 Nevertheless, it should be noted that, as suggested by 95% CIs (Table 1) , no method was able to exclude a difference in the effect of the two drugs on PP of less than 3 mmHg in this study.
APP is clearly advantageous since it has been found to correlate with end organ damage more closely 12, 27 and to have superior reproducibility compared to CPP. 25 In addition, APP monitoring offers the opportunity to assess the time effect profile of antihypertensive drug action. However, there is some evidence suggesting that the duration of antihypertensive drug action may also be assessed with home measurements using the morning-toevening HBP ratio as an alternative to the trough-topeak ratio. 7, 22, 23 Taking into account the findings of the present study regarding the usefulness of HPP, the value of this method in predicting hypertensive target organ damage and cardiovascular events needs to be examined.
Regarding the antihypertensive agents used in this study (ACEI and ARB), despite the fact that these act at different sites of the same system (renin-angiotensin system), they have several important differences, 28 the clinical importance of which has been investigated recently. 19, 29 Thus, it has been shown that the antihypertensive response to one of these drug classes cannot predict the response to the other 19 and that their combination provides additive antihypertensive effects. 29 Antihypertensive agents acting as vasodilators, such as ACEIs and ARBs, have been shown to improve arterial compliance. [30] [31] [32] Since PP is partly related to arterial stiffness, the decrease of PP observed in this study may be attributed to an improvement in arterial compliance with lisinopril as well as with losartan. The reduction of PP with these or other classes of antihypertensive drugs may contribute in decreasing end-systolic wall stress and, therefore, in reversing ventricular hypertrophy. 31, 33 What is not clear in this study is whether the greater effect of lisinopril on PP is due to its greater effect on BP or to specific effects of the drug on haemodynamic factors. A comparative study of an ARB with an ACEI of similar antihypertensive efficacy is needed to clarify this issue. Furthermore, whether drugs that give the same BP lowering effect but greater PP lowering offer additional cardiovascular protection remains to be established in future studies.
In conclusion, the present study suggests that the antihypertensive drugs may differ in their effects not only on BP but also on PP. Self-measurement at home appears to be at least as reliable as 24-h ambulatory monitoring in detecting clinically important differences in the effect of drugs on both BP and PP. Measurements in the clinic seem to be the least reliable method, particularly in the assessment of drug effects on PP. Therefore, HBP appears to be a useful alternative to 24-h ABP for clinical trials aiming to investigate the antihypertensive action of drugs in terms of their effects on both BP and PP.
